Sign In
Buy KTTA
$0.460
+0.0159 (+3.58%)
At Close: Jul 31, 2026
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
09:20am, Friday, 28'th Nov 2025
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron
-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomark
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin rat
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell?
02:15am, Saturday, 22'nd Nov 2025
Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report)'s stock price was down 29.6% during trading on Friday. The stock traded as low as $0.2810 and last traded at $0.2923. Approximately 3,259,5
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, wit
In new data, MEK inhibitor PAS-004 shows monotherapy partial response, favorable PK and safety profile, supporting best-in-class potential for NF1-PN.
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
08:39am, Friday, 29'th Aug 2025
MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board
07:02am, Wednesday, 11'th Jun 2025
MIAMI, June 11, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025
08:02am, Monday, 02'nd Jun 2025
PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
-- Demonstrates PAS-004's potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
07:02am, Wednesday, 14'th May 2025
Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.
Pasithea Therapeutics Announces Closing of $5 Million Public Offering
05:00pm, Wednesday, 07'th May 2025
Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.
